Koyfin Home > Directory > Health Care > LA Jolla Pharma > EBITDA / Interest Expenses

LA Jolla Pharma EBITDA / Interest Expenses Chart (LJPC)

LA Jolla Pharma annual/quarterly EBITDA / Interest Expenses from 2018 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • LA Jolla Pharma EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-3m a -178.47% increase of 6m year over year
  • LA Jolla Pharma EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-6m a -72.48% increase of 4m year over year
  • LA Jolla Pharma Annual EBITDA / Interest Expenses for 2019 was $-9m a -195.09% increase of 17m from 2018
  • LA Jolla Pharma Annual EBITDA / Interest Expenses for 2018 was $-25m
Other Ratios Metrics:
  • LA Jolla Pharma Total Debt / Capital for the quarter ending September 09, 2018 was $62m a 91.86% increase of 57m year over year
  • LA Jolla Pharma Other Liabilities for the quarter ending December 12, 2018 was $14m a 1.00% increase of 0m year over year
  • LA Jolla Pharma Total Debt / Equity for the quarter ending September 09, 2018 was $166m a 96.77% increase of 160m year over year
View Chart On Koyfin

Quarterly LJPC EBITDA / Interest Expenses Data

06/2020$-3m
03/2020$-3m
12/2019$-7m
09/2019$-9m
06/2019$-9m
03/2019$-10m
12/2018$-14m
09/2018$-16m
06/2018$-31m

Annual LJPC EBITDA / Interest Expenses Data

2019$-9m
2018$-25m